ESTRO 2024 - Abstract Book

S39 ESTRO 2024 disease, and would be a logical treatment approach if less toxicity could be predicted while maintaining an acceptable long-term cure rate. We will discuss target volumes, fusion with multiparametric MRI and/or PSMA PET, as well as fusion techniques (i.e. MR-US fusion) specific to salvage brachytherapy. Invited Speaker

3342

From an oncologist's perspective

Jesper Grau Eriksen

Aarhus University Hospital, Experimental Clinical Oncology, Aarhus, Denmark

Abstract:

Artificial Intelligence (AI) are about to become an important partner for the radiation oncologist in the daily clinical work. AI algorithms for organs at risk (OAR) delineation can be introduced as a commercial package or can be developed in-house in full or partly. In the presentation the introduction of a custom-made AI solution for OAR in our clinic will be described: The process, the concerns and the opportunities and a bit about the legal stuff. Our next step is the introduction of a GTV-T and N model and a solution to how the efficacy of such experimental algorithms can be tested is described. The presentation will also cover the potential for inter-institutional collaboration, QA and research as well as the dilemma on how we teach the next generation how to recognise properly delineated structures.

3344

From brachytherapy to interventional radiotherapy in the treatment of anal cancer

Luca Tagliaferri

Fondazione Policlinico Universitario Agostino Gemelli, IRCCS - Università Cattolica Del Sacro Cuore, Gemelli ART (Advanced Radiation Therapy), Rome, Italy

Abstract:

Anal cancer is rare tumor and it is more common in immunocompromised patients and smokers. Squamous cell cancer (SCC) is the most frequent histological type (80-85% of cases). Historically, abdomino-perineal resection with anal sphincter removal and permanent colostomy was the curative treatment option for anal cancer. In 1974, Nigro et al. introduced a novel combined modality treatment consisting in pelvic external beam radiation therapy (EBRT) plus chemotherapy (5-fluorouracil (5-FU) and mitomycin C (MMC), as neoadjuvant treatment before surgery. The authors reported higher local control rate (8-years LC: 78.5%), and reduction in surgical interventions (performed in 42.8% of patients), suggesting that it may be a valid alternative to surgery for the treatment of advanced anal cancer. Nowadays, definitive chemoradiation therapy (CCRT) represents the standard treatment option in primary Anal cancer. The local control is directly correlated with survival. In the past, several experiences reported an advantage in